Skip to main content
    L

    Lineage Cell Therapeutics Inc (LCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.82
    +0.02 (+2.99%)

    Market Cap: $201.12M

    Last updated: Nov 17, 2026 at 4:23 PM ET

    Lineage Cell Therapeutics Inc (LCTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Lineage Cell Therapeutics (LCTX) has a market cap of $201.12M and an enterprise value of $174.66M. Its share count is up 10.51% from a year earlier. It holds $26.46M more cash than debt, 13.16% of its market cap.

    Total Valuation

    Enterprise value is 13.16% below the market cap, as cash exceeds debt.

    Market Cap$201.12M
    Enterprise Value$174.66M
    Latest price (Nov 17, 2026)$0.82

    Key Dates

    The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 3, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.37% in the quarter ended Sep 30, 2026 and grew 15.73% a year over 2 years.

    Shares Outstanding252.91M
    Shares Change (YoY)+10.51%
    Shares Change (QoQ)+1.37%
    Share Count Growth (2Y CAGR)+15.73%

    Valuation Ratios

    Sales and book value multiples are 19.1x and 3.1x. Its year-end P/S ranged from 0.7x to 72.6x from 2016 to 2025.

    P/S Ratio19.1x
    Forward P/S13.2x
    P/B Ratio3.1x
    P/TBV Ratio8.4x

    Valuation history and multiples

    Enterprise Valuation

    EV / Earnings93.1x
    EV / Sales16.1x

    Price Statistics

    The stock is down 56.44% over 52 weeks and trades 17.17% below its 50-day average.

    Beta (1Y)1.27
    52-Week Change-56.44%
    1-Month Change-14.05%
    3-Month Change-25.55%
    6-Month Change-31.76%
    5-Year Change-56.14%
    10-Year Change-68.94%
    Total Return (1Y)-56.44%
    Total Return (5Y CAGR)-19.02%
    Max Drawdown (1Y)-59.43%
    Max Drawdown (3Y)-73.91%
    Sharpe Ratio (1Y)-1.36
    Correlation with SPY (1Y)0.31
    50-Day Average$0.99
    200-Day Average$1.29
    52-Week Range$0.77 to $1.99
    RSI (14 Days)36.2
    Average Volume (20 Days)2.19M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.96x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio5.96x
    Quick Ratio5.96x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -6.66% over the last 12 months, against a 5-year average of -55.21%.

    Return on Equity (ROE)2.80%
    Return on Assets (ROA)1.87%
    Return on Invested Capital (ROIC)-6.66%
    ROE (5Y Average)-56.53%
    ROA (5Y Average)-28.01%
    ROIC (5Y Average)-55.21%
    Asset Turnover0.11x
    Receivables Turnover10.21x

    Scores

    LCTX has an Altman Z-Score of -2.44, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-2.44
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $10.84M over the last 12 months is up 0.18% from the 12 months before.

    Revenue$10.84M
    Revenue Growth (YoY)+0.18%
    Gross Profit$10.77M
    Operating Income-$30.38M
    Pretax Income$326.00K
    Net Income$1.88M
    Reported EPS (TTM)-$0.08

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 66.99% of the $100.11M in total assets.

    Cash and Equivalents$26.50M
    Total Debt$39.00K
    Net Cash$26.46M
    Net Cash Per Share$0.10
    Working Capital$39.76M
    Shareholder Equity$67.06M
    Book Value Per Share$0.27
    Tangible Book Value$24.69M
    Tangible Book Per Share$0.10
    Total Assets$100.11M
    Total Liabilities$34.17M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $636.00K of capital spending, operating cash flow left -$26.46M of free cash flow.

    Operating Cash Flow-$25.82M
    Capital Expenditures$636.00K
    Free Cash Flow-$26.46M
    FCF Per Share-$0.10
    Depreciation and Amortization$763.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -280.34%.

    Gross Margin99.34%
    Operating Margin-280.34%
    Pretax Margin3.01%
    Net Margin17.32%
    FCF Margin-244.15%
    Gross Margin (5Y Average)90.04%

    Growth

    Revenue fell 0.33% a year over 3 years.

    Revenue Growth (3Y CAGR)-0.33%
    Revenue Growth (5Y CAGR)+51.46%
    Book Value Per Share Growth (2Y CAGR)-27.40%
    Tangible Book Per Share Growth (2Y CAGR)-48.61%

    Revenue and profit by year

    Dividends and Yields

    LCTX does not pay a dividend. Its free cash flow yield is -12.77%.

    FCF Yield-12.77%
    Buyback Yield-11.63%
    Shareholder Yield-11.63%

    Peer Position

    Against 6 similar companies, LCTX has the 3rd highest P/S.

    P/S Ratio19.1x vs 10.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)+0.18% vs +1.75% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 7.54% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+7.54%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LCTX

    What is LCTX's market cap?

    Lineage Cell Therapeutics has a market cap of $201.12M. Its enterprise value, which adds debt and subtracts cash, is $174.66M.

    How many shares of LCTX are outstanding?

    Lineage Cell Therapeutics has 252.91M shares outstanding. The count is up 10.51% from a year earlier.

    Does LCTX pay a dividend?

    No. Lineage Cell Therapeutics does not pay a dividend.

    How much debt does LCTX have?

    Lineage Cell Therapeutics has $39.00K of total debt and $26.50M of cash and equivalents, a net cash position of $26.46M.